4//SEC Filing
Guse Kyle 4
Accession 0001615774-19-000644
CIK 0001488039other
Filed
Jan 14, 7:00 PM ET
Accepted
Jan 15, 4:10 PM ET
Size
8.3 KB
Accession
0001615774-19-000644
Insider Transaction Report
Form 4
Guse Kyle
CFO & General Counsel
Transactions
- Award
Stock Option (Right to Buy)
2019-01-13+800,000→ 800,000 totalExercise: $1.36Exp: 2029-01-13→ Common Shares (800,000 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2019-01-13−700,000→ 0 totalExercise: $2.38Exp: 2028-06-27→ Common Shares (700,000 underlying)
Footnotes (3)
- [F1]The June 27, 2018 options are being rescinded and a new option is being granted in order to: (i) impose a shareholder-approval requirement for the new option grant, and (ii) remove the cash settlement feature and associated liability from the June 27, 2018 grant.
- [F2]Twenty-five percent of the options were vested as of the grant date (June 27, 2018), 50% of the options will vest quarterly over two years from the grant date, and the remaining 25% will vest upon achievement of certain milestones.
- [F3]Subject to stockholder approval of the option grant, the option will vest and be exercisable with respect to: (i) 25% of the underlying shares as of the grant date (January 13, 2019), (ii) 50% of the underlying shares over a two-year period (vesting ratably quarterly) from June 27, 2018, and (iii) 25% of the underlying shares upon achievement of certain milestones. If the option grant is not approved by stockholders, then the option will not be exercisable.
Documents
Issuer
ATOSSA GENETICS INC
CIK 0001488039
Entity typeother
Related Parties
1- filerCIK 0001566618
Filing Metadata
- Form type
- 4
- Filed
- Jan 14, 7:00 PM ET
- Accepted
- Jan 15, 4:10 PM ET
- Size
- 8.3 KB